(Corrects reference to Cooke to she from he in 2nd and 3rd
paragraph)
AMSTERDAM, March 16 (Reuters) - Europe's medicines watchdog
said on Tuesday the benefits of AstraZeneca's COVID-19
vaccine continue to outweigh the risks after several countries
halted its use due to concerns about blood clots.
EMA Executive Director Emer Cooke said there was no
indication that the blood clot incidents, which she called "very
rare" had been caused by the vaccine, but that experts were
assessing that possibility.
Trust in the safety of the vaccines was paramount and the
agency was carrying out a case-by-case evaluation, she said.
"The benefits continue to outweigh the risks, but this is a
serious concern and it does need serious and detailed scientific
evaluation. This is what we are involved in at the moment,"
Cooke told a news conference.
The results of its findings would be discussed during an EMA
review on Thursday after which the results would be made public,
Cooke said.
Sweden and Latvia on Tuesday suspended use of the vaccine,
bringing to more than a dozen the number of EU countries to act
since reports first emerged of thromboembolisms affecting people
after they got the AstraZeneca shot.
(Reporting by Toby Sterling and Bart Meijer; writing by Anthony
Deutsch; Editing by Catherine Evans and Philippa Fletcher)
Astrazeneca (AZN)
